1. Home
  2. MRAM vs VTYX Comparison

MRAM vs VTYX Comparison

Compare MRAM & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Everspin Technologies Inc.

MRAM

Everspin Technologies Inc.

HOLD

Current Price

$9.53

Market Cap

214.4M

Sector

Technology

ML Signal

HOLD

Logo Ventyx Biosciences Inc.

VTYX

Ventyx Biosciences Inc.

HOLD

Current Price

$8.73

Market Cap

713.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRAM
VTYX
Founded
2008
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
214.4M
713.6M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
MRAM
VTYX
Price
$9.53
$8.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$10.50
$14.60
AVG Volume (30 Days)
156.4K
1.7M
Earning Date
11-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$53,642,000.00
N/A
Revenue This Year
$11.00
N/A
Revenue Next Year
$9.39
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.34
$0.78
52 Week High
$12.27
$10.55

Technical Indicators

Market Signals
Indicator
MRAM
VTYX
Relative Strength Index (RSI) 56.61 51.15
Support Level $9.03 $8.98
Resistance Level $9.55 $9.35
Average True Range (ATR) 0.41 0.51
MACD 0.06 0.01
Stochastic Oscillator 78.78 58.25

Price Performance

Historical Comparison
MRAM
VTYX

About MRAM Everspin Technologies Inc.

Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC).

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Share on Social Networks: